QST, Blink Reflex and Nociceptive Flexion Reflex in Headache
NCT04585698 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2020-10-14
Summary
The aim of this study is to compare central and peripheric sensitization in headache patients at Baseline (T0) and 1 month after (T1) a treatment with an anti-CGRP (Fremanezumab-Ajovy).
Conditions
- Head Pain
Sponsors & Collaborators
-
University of Liege
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-10-31
- Primary Completion
- 2021-10-31
- Completion
- 2021-10-31
More Related Trials
-
A Controlled Trial of Erenumab in Migraine Prevention
NCT03812224 ·Status: COMPLETED ·Phase: PHASE3
-
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
NCT03977649 ·Status: COMPLETED ·Phase: PHASE4
-
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
NCT05854992 ·Status: COMPLETED
-
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
NCT05399485 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188 ·Status: RECRUITING ·Phase: NA
-
Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention
NCT01470352 ·Status: COMPLETED ·Phase: NA
-
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
NCT00821483 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
NCT03107052 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
NCT04458857 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
NCT05458011 ·Status: COMPLETED ·Phase: PHASE3
-
Validation of Venogenic Hypothesis for Cough, Exertional and Sexual Headaches
NCT00852748 ·Status: COMPLETED
-
Signs of Central Sensitization in Tension-type Headache
NCT06323720 ·Status: RECRUITING
-
Imaging the Migraine Brain Pre- and Post-Erenumab
NCT03773562 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
NCT04940390 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Prospective Study on the Presence of Typical Migraine Features in Nummular Headache Patients: The Numamig Study
NCT04299958 ·Status: COMPLETED
-
Effectiveness and Tolerability of Eptinezumab
NCT06409845 ·Status: RECRUITING
-
Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
NCT04069897 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Aspirin Resistance in Women With Migraine
NCT01257893 ·Status: WITHDRAWN ·Phase: NA
-
Prophylactic Treatment of Episodic Cluster Headache
NCT00184587 ·Status: COMPLETED ·Phase: PHASE2
-
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
NCT03308968 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
NCT02483585 ·Status: COMPLETED ·Phase: PHASE3
-
Prevalence and Determinants of Migraine Among Headache Patients
NCT07038499 ·Status: NOT_YET_RECRUITING
-
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
NCT04464707 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Adding an Oculomotor Therapy Treatment in Patients With Migraine
NCT05842642 ·Status: COMPLETED ·Phase: NA
-
Assessment of LBR-101 In Chronic Migraine
NCT02021773 ·Status: COMPLETED ·Phase: PHASE2